Oxford Nanopore Technologies (ONT) investor relations material

Market performance and growth

• Research accounted for 67% of revenues, growing over 15% despite funding challenges, especially in the Americas.

• Applied industrial segment grew 27%, targeting a GBP 1.5 billion synthetic biology market.

• Clinical segment grew 60% overall and 85% in the Americas, driven by adoption in rare and infectious diseases and oncology.

• Biopharma is a high-priority segment, estimated at GBP 3-4 billion, with growing interest in quality control applications.

• Total addressable market for clinical applications is around GBP 10 billion, with a serviceable market of 20-25%.

Technology differentiation and partnerships

• Long-read sequencing, rapid turnaround, and methylation analysis are key differentiators, enabling applications in rare disease, infectious disease, and oncology.

• Partnerships with Danaher, bioMérieux, and St. Jude's support expansion into regulated clinical and IVD markets.

• Adaptive sampling and software-driven panels allow targeted, cost-effective diagnostics.

• Technology enables direct DNA/RNA analysis, longer reads, and multi-omics data, setting it apart from competitors like PacBio and Roche.

• Competitors' solutions often rely on imputed long reads, while this platform provides direct, comprehensive data.

Biopharma and quality control applications

• Plasmid sequencing and mRNA vaccine production are key entry points, offering faster, more comprehensive, and cost-effective quality control.

• Technology is being evaluated for sterility testing and AAV workflows, leveraging infectious disease expertise.

• Personalized cancer vaccine QC is performed per patient, while broader biologics QC is done on large batches.

• Economic and quality benefits are driving adoption among pharmaceutical companies.

• Sequencing is expanding into areas not previously served by sequencing technologies.